

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/541,019
Confirmation Number	4031
Filing Date	June 28, 2005
First Named Inventor	Akira TSUJI
Art Unit	1615
Examiner Name	Jeffrey T PALENIK
Attorney Docket Number	Q88424

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	5158777		1992-10-27	Abramowitz, et al.	

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ²	Country Code ³	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	2.	0 800 828	EP	A1	1997-10-15	Teikoku Hormone Mfg Co Ltd.		

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	3.	European Search Report dated April 28, 2011, issued in corresponding European Appln. No. 04700783.6	
	4.	Leroux, J. C., et al., "Pharmacokinetics Of A Novel HIV-1 Protease Inhibitor Incorporated Into Biodegradable Or Enteric Nanoparticles Following Intravenous And Oral Administration To Mice", Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, US, Vol. 84, No. 12, December 1, 1995, pages 1387-1391, XP008049902.	
	5.	Tamai I., et al., "Functional Expression Of Intestinal Dipeptide/B-Lactam Antibiotic Transporter In <i>Xenopus</i> <i>Laevis</i> Oocytes", Biochemical Pharmacology, Pergamon, Oxford, GB, Vol. 48, No. 5, August 30, 1994, pages 881-888, XP025552891.	
	6.	Tamai I., et al., "Carrier-Mediated Approaches For Oral Drug Delivery", Advanced Drug Delivery Reviews, Vol. 20, No. 1, July 12, 1996, pages 5-32, XP002633372.	
	7.	Tsuji, A. et al., "Evidence For A Carrier-Mediated Transport System In The Small Intestine Available For FK-089 A New Cephalosporin Antibiotic Without An Amino Group", The Journal of Antibiotics, Vol. 39, no. 11, November 1, 1986, Pages 1592-1597., XP002633371.	

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.